AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CSL LIMITED

252.305

-3.095-1.21%

Volume:272.19K

Turnover:69.52M

Market Cap:122.17B

PE:28.00

High:255.760

Open:254.580

Low:252.050

Close:255.400

Loading ...

Overview Company News Filings

Top brokers name 3 ASX shares to buy today

Are these ASX 200 'moat' stocks undervalued right now?

1 big reason to buy CSL shares now

7 beaten-up ASX shares with 'strong balance sheets'

CSL, PME or REA: Which ASX stock will be the first to hit $500?

The one Australian stock to buy and hold forever in an ASX share portfolio

BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?

3 of the best Australian stocks to buy now

How to build a $1 million portfolio from zero with ASX shares

Shares vs. property: Experts reveal hot ASX stocks & suburb picks for investment in 2025

BRIEF-UK's MHRA Approves Andembry For Patients With Hereditary Angioedema To Prevent Angioedema Attacks

UK's Mhra: Approved Andembry for Patients Aged 12 Years and Older With Hereditary Angioedema (Hae) to Prevent Angioedema Attacks. - Website

THOMSON REUTERS

Our 2025 Investment Outlook – big themes for the year ahead

BRIEF-CSL Says Therapeutic Goods Administration Of Australia Approves Registration Of Andembry (Garadacimab)

Starting points matter

CSL Ltd - Therapeutic Goods Administration of Australia Approves Registration of CSL's Andembry (Garadacimab)

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/CSL.AU/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CSL.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","market":"AU","secType":"STK","nameCN":"CSL LIMITED","latestPrice":252.305,"timestamp":1741654350973,"preClose":255.4,"halted":0,"volume":272192,"delay":0,"changeRate":-0.012118,"change":-3.095,"floatShares":483945244,"shares":484206716,"eps":9.0151205,"lyrEps":8.707868,"pbRate":4.13,"amount":69517759,"amplitude":0.014526,"volumeRatio":1.137728,"dividePrice":4.377928,"prevYearClose":279.35,"fiveDayClose":262.614,"twentyDayClose":254.925},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","floatShares":483945244,"roa":"6.61%","roe":"14.35%","lyrEps":8.704487,"volumeRatio":1.137728,"shares":484206716,"dividePrice":4.376228,"high":255.76,"amplitude":0.014526,"preClose":255.4,"low":252.05,"week52Low":251.031,"pbRate":"4.14","psRate":"5.04","week52High":308.847,"institutionHeld":0,"latestPrice":252.305,"committee":0.696203,"eps":9.011620079726923,"divideRate":0.017302,"volume":272192,"delay":0,"ttmEps":9.011620079726923,"open":254.58,"prevYearClose":279.35,"prevWeekClose":257.604,"prevMonthClose":258.507,"prevQuarterClose":279.35,"fiveDayClose":262.614,"twentyDayClose":254.925,"sixtyDayClose":277.396},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSL.AU\",params:#limit:5,,,undefined,":[{"date":"2025-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2025-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-03-11","name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-09","payableDate":"2025-03-11","currency":"USD","dateTimestamp":1741525200000,"payDate":"2025-04-09"},{"date":"2025-02-11","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739228400000,"name":null,"time":"","dateTimestamp":1739192400000,"actualEps":null},{"date":"2024-09-09","symbol":"CSL.AU","amount":1.45,"announcedDate":"2024-08-13","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-09-10","defaultRemindTime":1725840000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-02","payableDate":"2024-09-10","currency":"USD","dateTimestamp":1725804000000,"payDate":"2024-10-02"},{"date":"2024-08-13","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1723507200000,"name":null,"time":"","dateTimestamp":1723471200000,"actualEps":null},{"date":"2024-03-11","symbol":"CSL.AU","amount":1.19,"announcedDate":"2024-02-13","type":"dividend","market":"AU","newRecordDate":"2024-03-12","defaultRemindTime":1710111600000,"name":"CSL 公司","recordDate":"2024-04-03","payableDate":"2024-03-12","currency":"USD","dateTimestamp":1710075600000,"payDate":"2024-04-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSL.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-09","value":1.469578,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-04-01","value":1.04,"currency":"USD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-30","value":1.062,"currency":"USD"},{"executeDate":"2022-03-07","recordDate":"2022-03-08","paymentDate":"2022-04-06","value":1.04,"currency":"USD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-10-05","value":1.062,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSL.AU\",pageSize:16,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2507975572","title":"Top brokers name 3 ASX shares to buy today","url":"https://stock-news.laohu8.com/highlight/detail?id=2507975572","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507975572?lang=en_us&edition=fundamental","pubTime":"2025-01-29 10:48","pubTimestamp":1738118899,"startTime":"0","endTime":"0","summary":"Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week. Three ASX shares that brok","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/29/top-brokers-name-3-asx-shares-to-buy-today-279/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU2237443978.SGD","CSL.AU","IE00B64QTZ34.USD","BK4516","BK4533","LU0012050646.USD","IE00B19Z3B42.SGD","IE0034235188.USD","LU2237443622.USD","LU1169589451.USD","BK7501","IE00BLDYK493.USD","LU2237443465.HKD","NXT.AU","LU0106831901.USD","BK4588","BK4552","IE00BSNM7G36.USD","IE0004086264.USD","LU0205194284.USD","APE.AU","BK7067","LU1668664300.SGD","IE00B19Z3581.USD","BK4550","LU1169590202.USD","LU2237443382.USD","IE0004091025.USD","BK4504","LU0106261612.USD","BK7043","BK4127","BK7511","BK4585","IE0002270589.USD","IE00BFXG1179.USD","LU2237443549.SGD","BK7508","HAE","LU0205193047.USD","LU1791807156.HKD","LU2237443895.HKD","BK7143","LU2237438978.USD","BK4198","BK7503"],"gpt_icon":0},{"id":"2507573167","title":"Are these ASX 200 'moat' stocks undervalued right now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2507573167","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507573167?lang=en_us&edition=fundamental","pubTime":"2025-01-29 08:09","pubTimestamp":1738109353,"startTime":"0","endTime":"0","summary":"One strategy investors may consider is buying S&P/ASX 200 Index (ASX: XJO) stocks in companies that have a wide economic 'moat'. An economic moat refers to a company's ability to maintain an advantage","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/29/are-these-asx-200-moat-stocks-undervalued-right-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","BK7511","BK7508","BK7501","CSL.AU","COH.AU","BK7007","XJO.AU"],"gpt_icon":0},{"id":"2507084522","title":"1 big reason to buy CSL shares now","url":"https://stock-news.laohu8.com/highlight/detail?id=2507084522","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507084522?lang=en_us&edition=fundamental","pubTime":"2025-01-29 06:24","pubTimestamp":1738103061,"startTime":"0","endTime":"0","summary":"If you have been thinking about buying CSL Ltd  shares, then read on. That's because Goldman Sachs has just named another reason to buy the biotechnology giant's shares. Why are CSL shares a buy?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/29/1-big-reason-to-buy-csl-shares-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4516","LU1169590202.USD","BK4550","IE0002270589.USD","LU1169589451.USD","CSL.AU","IE00B64QTZ34.USD","SG9999004303.SGD","LU2237443895.HKD","BK7001","HAE","BK4127","BK4588","BK7501","IE00BFXG1179.USD","LU0728928796.USD","LU2237443622.USD","BK7067","LU2237438978.USD","BK4086","LU2237443465.HKD","TGA.AU","SGXZ23171101.USD","IE00B19Z3581.USD","CSL","LU2237443549.SGD","BK7511","BK4585","LU0012050646.USD","LU0205193047.USD","LU2237443978.SGD","TGA","BK4213","IE00B19Z3B42.SGD","IE0034235188.USD","LU0106831901.USD","LU0205194284.USD","LU0106261612.USD","IE0004091025.USD","LU2237443382.USD","BK4156","IE0004086264.USD","LU1791807156.HKD","BK7508","IE00BLDYK493.USD","BK4533","IE00BSNM7G36.USD","BK4198","LU1668664300.SGD"],"gpt_icon":0},{"id":"2506558588","title":"7 beaten-up ASX shares with 'strong balance sheets'","url":"https://stock-news.laohu8.com/highlight/detail?id=2506558588","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506558588?lang=en_us&edition=fundamental","pubTime":"2025-01-28 09:28","pubTimestamp":1738027703,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index  has been unstoppable these past two years, but there are still some cheap ASX shares available.  Emma Fisher of Airlie Funds Management highlights some of these potentially cheap companies in a recent note.  The fund manager explained that Airlie started positions in each name toward the end of last year. These include:   BlueScope Steel Ltd  IDP Education Ltd  IGO Ltd  The Lottery Corporation Ltd  Ampol Ltd  BHP Group Ltd   CSL Ltd    Each of these businesses have \"strong balance sheets and good management\", and are positioned to generate solid returns according to the fundie. Let's take a look. Cheap ASX shares hard to find?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/28/7-beaten-up-asx-shares-with-strong-balance-sheets/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BHP.AU","BK7501","BK7508","BK7511","ALD.AU","BK7504","IGO.AU","BK7129","BSL.AU","BK7095","TLC.AU","BK7132","BK7065","BK7506","CSL.AU","BK7067","BK7078","XJO.AU","BK7507","IEL.AU"],"gpt_icon":0},{"id":"2506580077","title":"CSL, PME or REA: Which ASX stock will be the first to hit $500?","url":"https://stock-news.laohu8.com/highlight/detail?id=2506580077","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506580077?lang=en_us&edition=fundamental","pubTime":"2025-01-28 05:21","pubTimestamp":1738012871,"startTime":"0","endTime":"0","summary":"From left to right: Medallion's Michael Wayne, FNArena'sRudi Filapek-Vandyck & Marcus Today's Henry Jennings. As investors, we’re irresistibly drawn to milestones, and the past year has provided a jackpot of them. The ASX stormed past 8,000, Bitcoin soared beyond US$100,000, NVIDIA hit a mind-boggling US$3 trillion valuation, and Elon Musk’s fortune eclipsed the GDP of New Zealand at US$400 billion.Blame ‘round-number bias’ and the ‘salience effect’ - quirks of human psychology that make thresholds like a stock hitting $100 or an index crossing 10,000 feel larger than life and impossible to forget.The fascination isn’t just with indices; individual stock prices are also breaking records. Costco recently cracked US$1,000, Netflix is hot on its heels, and Nvidia’s stock has soared so high over the years that it has split six times. Its unadjusted price would now top US$14,000!With local heavyweights like Macquarie, Pro Medicus, Cochlear, CSL, and REA Group all trading above $200, what’s ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/csl-pme-or-rea-which-asx-stock-will-be-the-first-to-hit-500","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/csl-pme-or-rea-which-asx-stock-will-be-the-first-to-hit-500","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["SGXZ23171101.USD","LU0728928796.USD","PME.AU","LU1169589451.USD","XJO.AU","BK4212","BK4086","REA.AU","BK7501","BK7503","SG9999004303.SGD","MQG.AU","BK7067","BK7094","BK7007","CSL.AU","CSL","PME","XAO.AU","BK7511","BK7002","BK7046","LU1169590202.USD","XKO.AU","BK7508","COH.AU"],"gpt_icon":0},{"id":"2506058419","title":"The one Australian stock to buy and hold forever in an ASX share portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2506058419","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506058419?lang=en_us&edition=fundamental","pubTime":"2025-01-28 04:02","pubTimestamp":1738008120,"startTime":"0","endTime":"0","summary":"When it comes to building long-term wealth, few strategies are as effective as buy and hold investing. By focusing on high-quality companies and giving them time to grow, investors can take full advantage of the power of compounding. This approach not only reduces trading costs and taxes but also allows you to ride out the market's ups and downs without the stress of trying to time your buys and sells. Simply brilliant The beauty of buy and hold investing lies in its simplicity. Rather than constantly monitoring the market or chasing trends, investors can concentrate on finding fundamentally strong companies with sustainable competitive advantages, solid management teams, and long-term growth potential. These businesses tend to weather economic downturns better and emerge stronger when conditions improve. Over time, they can provide both capital appreciation and growing income streams through dividends. A key benefit of this strategy is that it rewards patience. The longer you hold ont","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/28/the-one-australian-stock-to-buy-and-hold-forever-in-an-asx-share-portfolio/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU0205193047.USD","LU1169590202.USD","BK4198","BK7511","LU0012050646.USD","XJO.AU","BK7501","BK7067","CSL.AU","IE00BLDYK493.USD","LU0205194284.USD","IE00B64QTZ34.USD","XKO.AU","XAO.AU","LU1169589451.USD","LU0106261612.USD","HAE","BK7508"],"gpt_icon":0},{"id":"2506832715","title":"BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2506832715","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506832715?lang=en_us&edition=fundamental","pubTime":"2025-01-28 00:40","pubTimestamp":1737996014,"startTime":"0","endTime":"0","summary":"Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with BioMarin Pharmaceutical  and CSL Limited Sponsored ADR . But which of these two stocks presents investors with the better value opportunity right now?We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.Currently, BioMarin Pharmaceutical has a Zacks Rank of #1 , while CSL Limited Sponsored ADR has a Zacks Rank of #3 . The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that BMRN has an improving earnings outlook. However, value investors will care about much more than just this.BioMarin Pharmaceutical Inc.  : Free Stock Analysis Report. CSL Limited Sponsored ADR ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bmrn-vs-cslly-stock-value-164014669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7501","CSLLY","BK4211","BK4139","IE00B7SZLL34.SGD","IE00B19Z3581.USD","BK4566","BK7508","BMRN","ISBC","IE00B19Z3B42.SGD","CSL.AU","IE0002270589.USD","BK7511","BK7067"],"gpt_icon":0},{"id":"2506398178","title":"3 of the best Australian stocks to buy now","url":"https://stock-news.laohu8.com/highlight/detail?id=2506398178","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506398178?lang=en_us&edition=fundamental","pubTime":"2025-01-27 04:27","pubTimestamp":1737923220,"startTime":"0","endTime":"0","summary":"There are a lot of Australian stocks to choose from on the share market, but which ones could be best buys?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/27/3-of-the-best-australian-stocks-to-buy-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CSL.AU","XAO.AU","BK7021","AX1.AU","BK7501","BK7511","XKO.AU","BK7508","BK7145","CWP.AU","BK7067","XJO.AU"],"gpt_icon":0},{"id":"2506436733","title":"How to build a $1 million portfolio from zero with ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2506436733","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506436733?lang=en_us&edition=fundamental","pubTime":"2025-01-27 02:34","pubTimestamp":1737916440,"startTime":"0","endTime":"0","summary":"Reaching a $1 million portfolio with ASX shares may seem like an impossible dream if you're just starting out, but it's entirely achievable with the right mindset, discipline, and strategy. The Austra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/27/how-to-build-a-1-million-portfolio-from-zero-with-asx-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7007","BK7155","IVV.AU","BK7511","BK7508","BK7099","RMD.AU","CSL.AU","BK7501","BK7510","GMG.AU","NDQ.AU","BK7067"],"gpt_icon":0},{"id":"2506892708","title":"Shares vs. property: Experts reveal hot ASX stocks & suburb picks for investment in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2506892708","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506892708?lang=en_us&edition=fundamental","pubTime":"2025-01-25 03:30","pubTimestamp":1737747000,"startTime":"0","endTime":"0","summary":"At a macro level, ASX shares outperformed investment property in 2024.  The benchmarkS&P/ASX 200 Index lifted 7.49% last year, with total gross returns of 11.44%. Meantime, the median national home value rose by 4.9%, with total gross returns  of 8.9%, according toCoreLogic data. Shares vs. property: What's the outlook for 2025?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/25/shares-vs-property-experts-reveal-hot-asx-stocks-suburb-picks-for-investment-in-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU0225283273.USD","LOV.AU","XRO.AU","LU1720051017.SGD","IE00BKVL7J92.USD","XJO.AU","LU0320765646.SGD","AMP.AU","BK7005","NXT.AU","XAO.AU","CSL.AU","BK7508","LU0106831901.USD","IE00BSNM7G36.USD","BK4534","HMC.AU","BK7040","LU0267386448.USD","LU2347655156.SGD","BK7083","LU2023251221.USD","PLS.AU","LU0795875169.SGD","WOW.AU","BOE.AU","LU2237443978.SGD","BK4552","LU2237443549.SGD","BHP.AU","LU1363072403.SGD","XKO.AU","LU1989772840.SGD","LU2237443382.USD","RRL.AU","LU0314104364.USD","LU1074936037.SGD","LU1162221912.USD","BK7162","LU2111349929.HKD","LU2237443895.HKD","LU2133065610.SGD","LU2089284900.SGD","WEB.AU","IE0004091025.USD","BK7112","LU1548497426.USD","LU0912757837.SGD","BK7104","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2505857315","title":"BRIEF-UK's MHRA Approves Andembry For Patients With Hereditary Angioedema To Prevent Angioedema Attacks","url":"https://stock-news.laohu8.com/highlight/detail?id=2505857315","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505857315?lang=en_us&edition=fundamental","pubTime":"2025-01-24 21:17","pubTimestamp":1737724621,"startTime":"0","endTime":"0","summary":"BRIEF-UK's MHRA Approves Andembry For Patients With Hereditary Angioedema To Prevent Angioedema AttacksJan 24  - UK's MHRA:UK'S MHRA: APPROVED ANDEMBRY FOR PATIENTS AGED 12 YEARS AND OLDER WITH HEREDITARY ANGIOEDEMA  TO PREVENT ANGIOEDEMA ATTACKS. - WEBSITESource text: [ID:]Further company coverage: CSL.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250124:nFWN3OK0VV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CSL.AU","BK7501","BK7067","BK7511"],"gpt_icon":0},{"id":"2505511298","title":"UK's Mhra: Approved Andembry for Patients Aged 12 Years and Older With Hereditary Angioedema (Hae) to Prevent Angioedema Attacks. - Website","url":"https://stock-news.laohu8.com/highlight/detail?id=2505511298","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505511298?lang=en_us&edition=fundamental","pubTime":"2025-01-24 20:33","pubTimestamp":1737722005,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250124:nFWN3OK0VV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","BK7508","CSL.AU","BK7511"],"gpt_icon":0},{"id":"2505855377","title":"Our 2025 Investment Outlook – big themes for the year ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2505855377","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505855377?lang=en_us&edition=fundamental","pubTime":"2025-01-24 14:23","pubTimestamp":1737699835,"startTime":"0","endTime":"0","summary":"Banks underperform the market in 2025 but don’t collapse. Figure 2:Resources and Energy underperformed the ASX200 by 30% in the past year. You can cut it many ways, but Santos  continues to look undervalued to us. The chart below illustrates the large gap that has opened between the cashflow driver  and the share price since 2021.On earnings, we see long term competitive threats in major business lines. For example, Macquarie has emerged as the price setter in residential mortgages driven by a cost and technology advantage. But in the year ahead, there is little to derail earnings. Revenues will be supported by an ok economy and rates that seem to be settling a bit higher, aiding interest income. On costs, there is upward pressure from both labour and technology costs requiring management to work hard to control them. Bad debts are likely a source of earnings upside given reasonable conditions and strong provisioning across all the banks.We continue to believe underweight the banks wil","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/our-2025-investment-outlook-big-themes-for-the-year-ahead","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/our-2025-investment-outlook-big-themes-for-the-year-ahead","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK4155","LU1496350171.SGD","ROE","BK4504","360.AU","LU0612318385.USD","LU1430597077.USD","LU2095319765.USD","SG9999014575.USD","BK7065","BK7130","STO.AU","LU0265550359.USD","BK7507","IE00BZ1G4Q59.USD","LU1069344957.HKD","CSL.AU","LU1066053197.SGD","LU2430703178.SGD","LU0203347892.USD","WTC.AU","CVX","LU2210150020.SGD","XOM","XJO.AU","XKO.AU","MQG.AU","LU0792757196.USD","ORG.AU","BK7067","LU1582987324.SGD","BK4534","LU2087621335.USD","BK4201","SG9999015358.SGD","LU0345781412.USD","XAO.AU","LU2125154778.USD","LU0889566641.SGD","LU2505996509.AUD","ALD.AU","SIG.AU","LU0149725797.USD","LU2430703251.USD","LU2360106947.USD","LU1929549753.HKD","BK4550","LU1582987597.SGD","BK7016"],"gpt_icon":1},{"id":"2505729710","title":"BRIEF-CSL Says Therapeutic Goods Administration Of Australia Approves Registration Of Andembry (Garadacimab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2505729710","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505729710?lang=en_us&edition=fundamental","pubTime":"2025-01-24 09:51","pubTimestamp":1737683505,"startTime":"0","endTime":"0","summary":"BRIEF-CSL Says Therapeutic Goods Administration Of Australia Approves Registration Of Andembry Jan 24  - CSL CSL.AX:THERAPEUTIC GOODS ADMINISTRATION OF AUSTRALIA APPROVES REGISTRATION OF CSL'S ANDEMBRY Further company coverage: CSL.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250124:nFWN3OJ1W3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","BK7501","BK7511","CSL.AU"],"gpt_icon":0},{"id":"2505705830","title":"Starting points matter","url":"https://stock-news.laohu8.com/highlight/detail?id=2505705830","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505705830?lang=en_us&edition=fundamental","pubTime":"2025-01-24 08:26","pubTimestamp":1737678367,"startTime":"0","endTime":"0","summary":"I learned a valuable lesson in July 2022, the last year the S&P/ASX 200 index posted a negative return, that starting points matter. I had gone on leave to have my second child in December 2021 as markets were making all-time highs, the cash rate was on the floor  and a raft of IPOs were hitting the ASX.When I returned six months later, it was like returning to a different planet: the S&P/ASX 200 had fallen 12%, the Fed and the RBA were aggressively raising rates, and what was most notable to me was the absolute consensus bearishness that had taken hold. Things were bad, and they were only going to get worse.So now we have a new starting point, 1 January 2025, and it’s a very different one. The average P/E multiple of the S&P/ASX 200 has re-rated from 12.7x in July 2022 to 17.7x today. In particular, the re-rating in the Big Four banks, which collectively drove almost 40% of the return of the ASX over the last two years, h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/starting-points-matter","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/starting-points-matter","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7507","BK7501","BK7132","BK7511","BK7065","CSL.AU","BHP.AU","BK7508","BK7129","BK7078","TLC.AU","IGO.AU","ALD.AU","BK7506","BK7067","BK7095","IEL.AU","BSL.AU","BK7504"],"gpt_icon":0},{"id":"2505026827","title":"CSL Ltd - Therapeutic Goods Administration of Australia Approves Registration of CSL's Andembry (Garadacimab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2505026827","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505026827?lang=en_us&edition=fundamental","pubTime":"2025-01-24 05:01","pubTimestamp":1737666069,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nFWN3OJ1W3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7508","BK7501","BK7067","BK7511"],"gpt_icon":0}],"pageSize":16,"totalPage":13,"pageCount":7,"totalSize":200}]}}